25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

MBRX (Moleculin) Stock Analysis
Buy, Hold or Sell?

Let's analyze Moleculin together

I guess you are interested in Moleculin Biotech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Moleculin’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Moleculin’s Price Targets

I'm going to help you getting a better view of Moleculin Biotech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Moleculin Biotech Inc

I send you an email if I find something interesting about Moleculin Biotech Inc.

1. Quick Overview

1.1. Quick analysis of Moleculin (30 sec.)










1.2. What can you expect buying and holding a share of Moleculin? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.24
Expected worth in 1 year
$-1.06
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$-0.82
Return On Investment
-199.8%

For what price can you sell your share?

Current Price per Share
$0.41
Expected price per share
$0.25 - $0.62
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Moleculin (5 min.)




Live pricePrice per Share (EOD)
$0.41
Intrinsic Value Per Share
$-2.25 - $-2.36
Total Value Per Share
$-2.49 - $-2.59

2.2. Growth of Moleculin (5 min.)




Is Moleculin growing?

Current yearPrevious yearGrowGrow %
How rich?-$7.1m$25.1m-$23.5m-1,486.5%

How much money is Moleculin making?

Current yearPrevious yearGrowGrow %
Making money-$6.6m-$6.2m-$345.7k-5.2%
Net Profit Margin-2,927.4%-938.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Moleculin (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#786 / 853

Most Revenue
#615 / 853

Most Profit
#455 / 853

Most Efficient
#747 / 853
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Moleculin?

Welcome investor! Moleculin's management wants to use your money to grow the business. In return you get a share of Moleculin.

First you should know what it really means to hold a share of Moleculin. And how you can make/lose money.

Speculation

The Price per Share of Moleculin is $0.412. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Moleculin.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Moleculin, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.24. Based on the TTM, the Book Value Change Per Share is $-0.21 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Moleculin.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.25-61.4%-0.22-53.3%-0.21-50.6%-0.22-52.4%-0.19-45.7%-0.15-36.5%
Usd Book Value Change Per Share-0.24-57.9%-0.21-50.0%-0.19-45.3%-0.20-49.2%-0.04-9.2%-0.01-1.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.24-57.9%-0.21-50.0%-0.19-45.3%-0.20-49.2%-0.04-9.2%-0.01-1.4%
Usd Price Per Share0.30-1.45-2.68-1.68-1.88-1.79-
Price to Earnings Ratio-0.30--2.57--4.09--2.57--3.11--5.96-
Price-to-Total Gains Ratio-1.27--12.21--18.14--11.52--12.30--15.48-
Price to Book Ratio-1.27-179.76-3.91-61.41-37.29-20.16-
Price-to-Total Gains Ratio-1.27--12.21--18.14--11.52--12.30--15.48-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.412
Number of shares2427
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.21-0.04
Usd Total Gains Per Share-0.21-0.04
Gains per Quarter (2427 shares)-499.54-91.57
Gains per Year (2427 shares)-1,998.16-366.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-1998-20080-366-376
20-3996-40060-733-742
30-5994-60040-1099-1108
40-7993-80020-1465-1474
50-9991-100000-1831-1840
60-11989-119980-2198-2206
70-13987-139960-2564-2572
80-15985-159940-2930-2938
90-17983-179920-3296-3304
100-19982-199900-3663-3670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.040.00.00.0%
Book Value Change Per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%10.030.00.025.0%10.030.00.025.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.040.00.0%
Total Gains per Share0.04.00.00.0%0.012.00.00.0%2.018.00.010.0%10.030.00.025.0%10.030.00.025.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Moleculin Biotech Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.239-0.206-14%-0.187-22%-0.203-15%-0.038-84%-0.006-98%
Book Value Per Share---0.2370.052-552%0.832-129%0.837-128%1.338-118%0.906-126%
Current Ratio--1.1471.386-17%4.212-73%4.456-74%8.646-87%6.022-81%
Debt To Asset Ratio--1.3320.914+46%0.259+414%0.428+211%0.326+308%1.115+19%
Debt To Equity Ratio---125.817-100%0.366-100%42.103-100%25.366-100%12.836-100%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value---12078335.00032010184.250-138%91460387.313-113%61914040.604-120%83220616.038-115%74581879.878-116%
Eps---0.253-0.220-13%-0.208-18%-0.216-15%-0.188-26%-0.150-41%
Ev To Ebitda Ratio--0.397-1.192+400%-3.473+975%-2.224+661%-3.292+930%-6.452+1726%
Free Cash Flow Per Share---0.185-0.177-4%-0.213+15%-0.202+9%-0.188+2%-0.137-26%
Free Cash Flow To Equity Per Share---0.005-0.027+413%-0.176+3250%-0.140+2554%0.108-105%0.060-109%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%181.932-99%
Intrinsic Value_10Y_max---2.355----------
Intrinsic Value_10Y_min---2.249----------
Intrinsic Value_1Y_max---0.725----------
Intrinsic Value_1Y_min---0.713----------
Intrinsic Value_3Y_max---1.807----------
Intrinsic Value_3Y_min---1.732----------
Intrinsic Value_5Y_max---2.438----------
Intrinsic Value_5Y_min---2.295----------
Market Cap12445490.000+27%9122665.00043918684.250-79%80925137.313-89%50824873.938-82%56850666.038-84%53952558.488-83%
Net Profit Margin----29.2740%-9.3840%-12.8860%-15221.8390%-7618.8810%
Operating Margin----36.7640%-9.6030%-15.4560%-20820.6370%-10416.9960%
Operating Ratio---36.887-100%9.623-100%15.503-100%20970.666-100%10492.011-100%
Pb Ratio-1.737-36%-1.273179.756-101%3.909-133%61.408-102%37.294-103%20.157-106%
Pe Ratio-0.407-36%-0.299-2.572+762%-4.085+1269%-2.570+761%-3.106+940%-5.965+1898%
Price Per Share0.412+27%0.3021.454-79%2.679-89%1.683-82%1.882-84%1.786-83%
Price To Free Cash Flow Ratio-0.557-36%-0.409-2.013+393%-3.178+678%-2.081+409%-2.663+552%-5.143+1159%
Price To Total Gains Ratio-1.727-36%-1.266-12.211+865%-18.141+1333%-11.522+810%-12.298+872%-15.480+1123%
Quick Ratio--0.9551.140-16%3.703-74%4.047-76%8.190-88%5.650-83%
Return On Assets---0.354-0.306-14%-0.185-48%-0.205-42%-0.152-57%-1.812+412%
Return On Equity----38.7420%-0.2570%-13.0470%-7.8660%-4.0090%
Total Gains Per Share---0.239-0.206-14%-0.187-22%-0.203-15%-0.038-84%-0.006-98%
Usd Book Value---7165000.0001583750.000-552%25125750.000-129%25283166.667-128%40405850.000-118%27371876.550-126%
Usd Book Value Change Per Share---0.239-0.206-14%-0.187-22%-0.203-15%-0.038-84%-0.006-98%
Usd Book Value Per Share---0.2370.052-552%0.832-129%0.837-128%1.338-118%0.906-126%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value---12078335.00032010184.250-138%91460387.313-113%61914040.604-120%83220616.038-115%74581879.878-116%
Usd Eps---0.253-0.220-13%-0.208-18%-0.216-15%-0.188-26%-0.150-41%
Usd Free Cash Flow---5582000.000-5335500.000-4%-6436500.000+15%-6095500.000+9%-5692050.000+2%-4129195.467-26%
Usd Free Cash Flow Per Share---0.185-0.177-4%-0.213+15%-0.202+9%-0.188+2%-0.137-26%
Usd Free Cash Flow To Equity Per Share---0.005-0.027+413%-0.176+3250%-0.140+2554%0.108-105%0.060-109%
Usd Market Cap12445490.000+27%9122665.00043918684.250-79%80925137.313-89%50824873.938-82%56850666.038-84%53952558.488-83%
Usd Price Per Share0.412+27%0.3021.454-79%2.679-89%1.683-82%1.882-84%1.786-83%
Usd Profit---7640000.000-6637500.000-13%-6291750.000-18%-6608833.333-13%-5733500.000-25%-4176940.725-45%
Usd Revenue---47250.000-100%203000.000-100%83416.667-100%50056.450-100%25253.225-100%
Usd Total Gains Per Share---0.239-0.206-14%-0.187-22%-0.203-15%-0.038-84%-0.006-98%
 EOD+6 -2MRQTTM+8 -25YOY+11 -223Y+11 -225Y+9 -2410Y+7 -27

3.3 Fundamental Score

Let's check the fundamental score of Moleculin Biotech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.407
Price to Book Ratio (EOD)Between0-1-1.737
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.955
Current Ratio (MRQ)Greater than11.147
Debt to Asset Ratio (MRQ)Less than11.332
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.354
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Moleculin Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.363
Ma 20Greater thanMa 500.433
Ma 50Greater thanMa 1000.569
Ma 100Greater thanMa 2000.657
OpenGreater thanClose0.389
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Moleculin Biotech Inc

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Fundamental data was last updated by Penke on 2025-09-04 04:40:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Moleculin earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Moleculin to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Moleculin Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,927.4%+2,927.4%
TTM-2,927.4%YOY-938.4%-1,989.0%
TTM-2,927.4%5Y-1,522,183.9%+1,519,256.5%
5Y-1,522,183.9%10Y-761,888.1%-760,295.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--86.1%+86.1%
TTM-2,927.4%-169.5%-2,757.9%
YOY-938.4%-209.8%-728.6%
3Y-1,288.6%-284.5%-1,004.1%
5Y-1,522,183.9%-380.6%-1,521,803.3%
10Y-761,888.1%-519.5%-761,368.6%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Moleculin is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Moleculin to theΒ Biotechnology industry mean.
  • -35.4% Return on Assets means thatΒ Moleculin generatedΒ $-0.35 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Moleculin Biotech Inc:

  • The MRQ is -35.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -30.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-35.4%TTM-30.6%-4.8%
TTM-30.6%YOY-18.5%-12.1%
TTM-30.6%5Y-15.2%-15.4%
5Y-15.2%10Y-181.2%+166.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.4%-12.1%-23.3%
TTM-30.6%-12.0%-18.6%
YOY-18.5%-11.2%-7.3%
3Y-20.5%-12.0%-8.5%
5Y-15.2%-11.7%-3.5%
10Y-181.2%-13.8%-167.4%
4.3.1.3. Return on Equity

Shows how efficient Moleculin is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Moleculin to theΒ Biotechnology industry mean.
  • 0.0% Return on Equity means Moleculin generated $0.00Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Moleculin Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3,874.2%+3,874.2%
TTM-3,874.2%YOY-25.7%-3,848.5%
TTM-3,874.2%5Y-786.6%-3,087.6%
5Y-786.6%10Y-400.9%-385.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--14.3%+14.3%
TTM-3,874.2%-15.2%-3,859.0%
YOY-25.7%-15.2%-10.5%
3Y-1,304.7%-16.8%-1,287.9%
5Y-786.6%-17.5%-769.1%
10Y-400.9%-19.6%-381.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Moleculin Biotech Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Moleculin is operatingΒ .

  • Measures how much profit Moleculin makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Moleculin to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Moleculin Biotech Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-3,676.4%+3,676.4%
TTM-3,676.4%YOY-960.3%-2,716.0%
TTM-3,676.4%5Y-2,082,063.7%+2,078,387.3%
5Y-2,082,063.7%10Y-1,041,699.6%-1,040,364.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--161.5%+161.5%
TTM-3,676.4%-286.7%-3,389.7%
YOY-960.3%-254.3%-706.0%
3Y-1,545.6%-270.1%-1,275.5%
5Y-2,082,063.7%-356.3%-2,081,707.4%
10Y-1,041,699.6%-528.7%-1,041,170.9%
4.3.2.2. Operating Ratio

Measures how efficient Moleculin is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM36.887-36.887
TTM36.887YOY9.623+27.264
TTM36.8875Y20,970.666-20,933.779
5Y20,970.66610Y10,492.011+10,478.655
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.929-1.929
TTM36.8872.934+33.953
YOY9.6232.982+6.641
3Y15.5033.799+11.704
5Y20,970.6664.893+20,965.773
10Y10,492.0116.841+10,485.170
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Moleculin Biotech Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Moleculin is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.15Β means the company has $1.15 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 1.147. The company is just able to pay all its short-term debts.
  • The TTM is 1.386. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.147TTM1.386-0.239
TTM1.386YOY4.212-2.826
TTM1.3865Y8.646-7.260
5Y8.64610Y6.022+2.625
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1473.480-2.333
TTM1.3863.736-2.350
YOY4.2124.133+0.079
3Y4.4564.591-0.135
5Y8.6465.762+2.884
10Y6.0226.154-0.132
4.4.3.2. Quick Ratio

Measures if Moleculin is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Moleculin to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.96Β means the company can pay off $0.96 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 0.955. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.140. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ0.955TTM1.140-0.185
TTM1.140YOY3.703-2.563
TTM1.1405Y8.190-7.051
5Y8.19010Y5.650+2.541
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9552.930-1.975
TTM1.1403.192-2.052
YOY3.7033.990-0.287
3Y4.0474.381-0.334
5Y8.1905.837+2.353
10Y5.6506.540-0.890
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Moleculin Biotech Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of MoleculinΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Moleculin to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.33Β means that Moleculin assets areΒ financed with 133.2% credit (debt) and the remaining percentage (100% - 133.2%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 1.332. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 0.914. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.332TTM0.914+0.418
TTM0.914YOY0.259+0.655
TTM0.9145Y0.326+0.588
5Y0.32610Y1.115-0.789
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3320.339+0.993
TTM0.9140.359+0.555
YOY0.2590.334-0.075
3Y0.4280.341+0.087
5Y0.3260.349-0.023
10Y1.1150.379+0.736
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Moleculin is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Moleculin to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Moleculin Biotech Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM125.817-125.817
TTM125.817YOY0.366+125.451
TTM125.8175Y25.366+100.451
5Y25.36610Y12.836+12.531
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.391-0.391
TTM125.8170.432+125.385
YOY0.3660.427-0.061
3Y42.1030.462+41.641
5Y25.3660.459+24.907
10Y12.8360.514+12.322
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Moleculin generates.

  • Above 15 is considered overpriced butΒ always compareΒ Moleculin to theΒ Biotechnology industry mean.
  • A PE ratio of -0.30 means the investor is paying $-0.30Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Moleculin Biotech Inc:

  • The EOD is -0.407. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.299. Based on the earnings, the company is expensive. -2
  • The TTM is -2.572. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.407MRQ-0.299-0.109
MRQ-0.299TTM-2.572+2.273
TTM-2.572YOY-4.085+1.514
TTM-2.5725Y-3.106+0.534
5Y-3.10610Y-5.965+2.859
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.407-2.542+2.135
MRQ-0.299-2.355+2.056
TTM-2.572-2.660+0.088
YOY-4.085-3.770-0.315
3Y-2.570-3.843+1.273
5Y-3.106-6.412+3.306
10Y-5.965-7.084+1.119
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Moleculin Biotech Inc:

  • The EOD is -0.557. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.409. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.013. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.557MRQ-0.409-0.149
MRQ-0.409TTM-2.013+1.605
TTM-2.013YOY-3.178+1.164
TTM-2.0135Y-2.663+0.650
5Y-2.66310Y-5.143+2.479
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.557-3.327+2.770
MRQ-0.409-3.016+2.607
TTM-2.013-3.645+1.632
YOY-3.178-4.377+1.199
3Y-2.081-5.257+3.176
5Y-2.663-8.487+5.824
10Y-5.143-9.626+4.483
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Moleculin is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of -1.27 means the investor is paying $-1.27Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Moleculin Biotech Inc:

  • The EOD is -1.737. Based on the equity, the company is expensive. -2
  • The MRQ is -1.273. Based on the equity, the company is expensive. -2
  • The TTM is 179.756. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.737MRQ-1.273-0.464
MRQ-1.273TTM179.756-181.029
TTM179.756YOY3.909+175.847
TTM179.7565Y37.294+142.463
5Y37.29410Y20.157+17.136
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.7372.201-3.938
MRQ-1.2732.007-3.280
TTM179.7562.189+177.567
YOY3.9092.409+1.500
3Y61.4082.558+58.850
5Y37.2943.764+33.530
10Y20.1574.462+15.695
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Moleculin Biotech Inc.

4.8.1. Institutions holding Moleculin Biotech Inc

Institutions are holding 6.667% of the shares of Moleculin Biotech Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Citigroup Inc0.6037085283824952958.9311
2025-06-30XTX Topco Ltd0.52530.00097421762642541.1836
2025-03-31Cetera Investment Advisers0.49550.000170000700000
2025-03-31LPL Financial Corp0.3262046080486511.804
2025-06-30VERUS CAPITAL PARTNERS, LLC0.30440.001143000430000
2025-06-30Vanguard Group Inc0.21903093500
2025-03-31Geode Capital Management, LLC0.1844026057403318.3118
2025-06-30CAMBRIDGE Invest RESEARCH ADVISORS, INC.0.090501278100
2025-03-31BlackRock Inc0.087601238000
2025-06-30BB&T Corp.0.074301050000
2025-06-30Tower Research Capital LLC0.0278039212573190.8754
2025-06-30Stone House Investment Management, LLC0.02340.0002330033000
2025-03-31Newbridge Financial Services Group, Inc.0.00970.0003136700
2025-03-31Morgan Stanley - Brokerage Accounts0.00660926500117.3709
2025-03-31SBI Securities Co Ltd0.0053074634184.1975
2025-03-31Barclays PLC0.002403443440
2025-06-30Bogart Wealth, LLC0.0021030000
2025-03-31Sandy Spring Bank0.000608900
2025-03-31Advisor Group Holdings, Inc.0.0003043-6-12.2449
2025-03-31FMR Inc0.0002034340
Total 2.98930.0026422303+274121+64.9%

4.9.2. Funds holding Moleculin Biotech Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr0.28960.00018748657172188.5993
2025-06-30Fidelity Extended Market Index0.061201849100
2025-06-30Fidelity Series Total Market Index0.019405848-8477-59.1763
2025-06-30Fidelity Total Market Index0.00680205500
2025-06-30NT Ext Equity Mkt Idx Fd - NL0.00580174300
2025-06-30NT Ext Equity Mkt Idx Fd - L0.00580173800
2025-06-30Northern Trust Extended Eq Market Idx0.00580173800
2025-06-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.004501353-3-0.2212
2025-06-30Spartan Total Market Index Pool G0.00370112100
2025-07-31State St US Extended Mkt Indx NL Cl C0.0026078000
2025-07-31Vanguard U.S. Eq Idx Β£ Acc0.0021062100
2025-06-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.001604907317.506
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.001404144140
2025-03-31SSgA U.S. Total Market Index Strategy0.0011032772.1875
2025-07-31State St US Ttl Mkt Indx NL Cl A0.0007022000
2025-06-30Northern Trust Wilshire 50000.000308300
2025-06-30Fidelity U.S. Equity Index Ins Trust001500
Total 0.41240.0001124523+49186+39.5%

5.3. Insider Transactions

Insiders are holding 3.517% of the shares of Moleculin Biotech Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-23Jonathan P FosterBUY2702700.37
2025-06-23Walter V KlempBUY6756750.37
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-06-302024-09-302024-12-312025-03-312025-06-30
Total Stockholder Equity 17,705-10,2267,479-1,5005,979-5,93742-7,207-7,165
Net Invested Capital  17,705-10,2267,479-1,5005,979-5,93742-7,207-7,165



5.2. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets21,593
Total Liabilities28,758
Total Stockholder Equity-7,165
 As reported
Total Liabilities 28,758
Total Stockholder Equity+ -7,165
Total Assets = 21,593

Assets

Total Assets21,593
Total Current Assets9,076
Long-term Assets12,517
Total Current Assets
Cash And Cash Equivalents 7,557
Other Current Assets 1,519
Total Current Assets  (as reported)9,076
Total Current Assets  (calculated)9,076
+/-0
Long-term Assets
Property Plant Equipment 370
Intangible Assets 11,148
Long-term Assets Other 999
Long-term Assets  (as reported)12,517
Long-term Assets  (calculated)12,517
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities7,913
Long-term Liabilities20,845
Total Stockholder Equity-7,165
Total Current Liabilities
Accounts payable 3,721
Other Current Liabilities 4,192
Total Current Liabilities  (as reported)7,913
Total Current Liabilities  (calculated)7,913
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt420
Long-term Liabilities  (as reported)20,845
Long-term Liabilities  (calculated)420
+/- 20,425
Total Stockholder Equity
Common Stock30
Retained Earnings -167,443
Accumulated Other Comprehensive Income -38
Other Stockholders Equity 160,286
Total Stockholder Equity (as reported)-7,165
Total Stockholder Equity (calculated)-7,165
+/-0
Other
Capital Stock30
Cash and Short Term Investments 7,557
Common Stock Shares Outstanding 15,526
Liabilities and Stockholders Equity 21,593
Net Debt -7,265
Net Invested Capital -7,165
Net Working Capital 1,163
Property Plant and Equipment Gross 469
Short Long Term Debt Total 292



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
> Total Assets 
110
28
290
19,233
17,574
16,393
20,317
21,249
20,633
19,483
24,929
24,066
20,899
19,585
21,298
31,854
30,398
25,235
25,472
31,380
27,144
29,031
99,784
93,534
88,702
84,090
78,801
73,255
65,372
57,422
51,062
47,115
39,523
38,217
30,845
25,575
23,394
16,925
21,013
21,593
21,59321,01316,92523,39425,57530,84538,21739,52347,11551,06257,42265,37273,25578,80184,09088,70293,53499,78429,03127,14431,38025,47225,23530,39831,85421,29819,58520,89924,06624,92919,48320,63321,24920,31716,39317,57419,23329028110
   > Total Current Assets 
110
28
290
7,560
6,429
5,222
9,150
10,081
9,463
8,302
13,748
12,892
9,360
7,974
9,613
20,202
18,586
13,484
13,787
19,749
15,250
17,198
88,019
81,836
77,070
72,497
67,260
61,322
53,493
45,596
39,289
35,380
27,603
26,273
18,957
13,731
11,606
5,194
9,340
9,076
9,0769,3405,19411,60613,73118,95726,27327,60335,38039,28945,59653,49361,32267,26072,49777,07081,83688,01917,19815,25019,74913,78713,48418,58620,2029,6137,9749,36012,89213,7488,3029,46310,0819,1505,2226,4297,56029028110
       Cash And Cash Equivalents 
87
28
260
7,245
6,184
5,007
8,881
9,272
8,736
7,714
13,114
11,722
8,600
7,134
8,782
18,695
15,409
10,735
11,649
16,734
12,795
15,173
86,293
79,506
75,178
70,903
66,104
57,999
50,392
43,145
37,265
32,172
24,579
23,550
16,824
10,845
9,405
4,278
7,716
7,557
7,5577,7164,2789,40510,84516,82423,55024,57932,17237,26543,14550,39257,99966,10470,90375,17879,50686,29315,17312,79516,73411,64910,73515,40918,6958,7827,1348,60011,72213,1147,7148,7369,2728,8815,0076,1847,2452602887
       Net Receivables 
0
0
30
0
0
0
0
0
0
0
0
0
0
56
0
0
316
11
1
13
6
1
1
0
0
45
27
33
10
22
0
12
0
99
99
9
0
20
6
0
0620099999012022103327450011613111316005600000000003000
       Other Current Assets 
46
0
30
315
245
215
269
809
1,454
588
1,268
2,340
1,520
955
1,662
3,014
2,861
2,738
2,137
3,002
2,449
2,024
3,452
4,660
3,784
1,063
572
2,386
2,284
1,628
2,024
2,293
3,024
2,624
2,133
2,877
2,201
896
1,618
1,519
1,5191,6188962,2012,8772,1332,6243,0242,2932,0241,6282,2842,3865721,0633,7844,6603,4522,0242,4493,0022,1372,7382,8613,0141,6629551,5202,3401,2685881,45480926921524531530046
   > Long-term Assets 
0
0
0
11,674
11,145
11,171
11,167
11,168
11,170
11,181
11,181
11,174
11,539
11,611
11,685
11,652
11,812
11,751
11,685
11,631
11,894
11,833
11,765
11,698
11,632
11,593
11,541
11,933
11,879
11,826
11,773
11,735
11,920
11,944
11,888
11,844
11,788
11,731
11,673
12,517
12,51711,67311,73111,78811,84411,88811,94411,92011,73511,77311,82611,87911,93311,54111,59311,63211,69811,76511,83311,89411,63111,68511,75111,81211,65211,68511,61111,53911,17411,18111,18111,17011,16811,16711,17111,14511,674000
       Property Plant Equipment 
0
0
0
7
16
23
19
20
22
33
33
26
391
463
537
504
664
603
537
483
746
685
617
550
484
445
393
785
731
678
625
587
772
796
740
696
640
583
525
370
37052558364069674079677258762567873178539344548455061768574648353760366450453746339126333322201923167000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,137
11,137
0
0
0
0
0
0000011,13711,137000000000000000000000000000000000
       Intangible Assets 
0
0
0
11,666
11,129
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11
11,148
11,148
11,148
11,148
11,148
11,148
11,14811,14811,14811,14811,14811,1481111,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,14811,12911,666000
       Other Assets 
0
0
30
11,173
11,129
11,148
11,148
11,148
11,148
11,148
11,148
11,148
11,148
0
0
0
0
0
0
0
0
685
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000006850000000011,14811,14811,14811,14811,14811,14811,14811,14811,12911,1733000
> Total Liabilities 
333
773
978
2,003
1,330
1,433
4,175
1,980
1,982
2,365
4,359
7,318
5,931
5,313
6,616
9,762
11,423
9,664
10,180
15,751
12,677
11,271
11,268
8,834
7,443
5,097
6,136
6,896
6,955
5,231
5,378
6,847
4,385
12,144
9,258
7,870
15,915
10,946
20,971
28,758
28,75820,97110,94615,9157,8709,25812,1444,3856,8475,3785,2316,9556,8966,1365,0977,4438,83411,26811,27112,67715,75110,1809,66411,4239,7626,6165,3135,9317,3184,3592,3651,9821,9804,1751,4331,3302,003978773333
   > Total Current Liabilities 
333
773
978
1,403
1,280
1,345
2,204
1,830
1,832
2,215
1,799
4,116
3,129
3,878
6,436
9,591
11,119
3,570
3,235
3,739
3,438
2,920
4,578
3,350
3,656
3,622
4,834
5,859
6,362
4,819
5,032
6,554
3,888
6,815
5,408
5,746
5,593
5,359
6,896
7,913
7,9136,8965,3595,5935,7465,4086,8153,8886,5545,0324,8196,3625,8594,8343,6223,6563,3504,5782,9203,4383,7393,2353,57011,1199,5916,4363,8783,1294,1161,7992,2151,8321,8302,2041,3451,2801,403978773333
       Short-term Debt 
250
450
615
432
298
296
108
1,185
743
503
463
451
369
180
33
35
100
103
107
110
114
118
122
126
115
96
77
98
112
116
0
0
176
200
218
224
232
240
248
0
02482402322242182001760011611298779611512612211811411010710310035331803694514635037431,185108296298432615450250
       Short Long Term Debt 
0
450
0
0
0
296
108
0
0
0
0
0
0
0
33
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000003300000001082960004500
       Accounts payable 
63
323
363
721
982
1,049
858
645
1,089
810
570
1,676
785
1,246
2,799
1,257
3,188
2,153
1,206
1,918
1,343
1,129
1,928
1,505
1,390
1,364
2,224
3,184
3,568
2,095
1,939
4,136
2,008
2,498
2,104
2,833
2,550
2,030
2,706
3,721
3,7212,7062,0302,5502,8332,1042,4982,0084,1361,9392,0953,5683,1842,2241,3641,3901,5051,9281,1291,3431,9181,2062,1533,1881,2572,7991,2467851,6765708101,0896458581,04998272136332363
       Other Current Liabilities 
20
88
363
250
38
88
1,238
1,185
743
1,405
1,229
2,440
2,344
2,632
3,604
8,299
7,831
1,314
1,922
1,711
1,981
1,673
2,528
1,719
2,151
2,162
2,533
2,577
2,682
2,608
3,093
2,418
1,792
4,117
3,086
2,689
2,811
3,089
3,942
4,192
4,1923,9423,0892,8112,6893,0864,1171,7922,4183,0932,6082,6822,5772,5332,1622,1511,7192,5281,6731,9811,7111,9221,3147,8318,2993,6042,6322,3442,4401,2291,4057431,1851,23888382503638820
   > Long-term Liabilities 
0
0
615
600
50
0
1,971
150
150
150
2,560
3,202
2,802
1,435
180
171
304
6,094
6,945
12,012
9,239
8,351
6,690
5,484
3,787
1,475
1,302
1,037
593
412
346
293
497
5,329
3,850
2,124
10,322
5,587
14,075
20,845
20,84514,0755,58710,3222,1243,8505,3294972933464125931,0371,3021,4753,7875,4846,6908,3519,23912,0126,9456,0943041711801,4352,8023,2022,5601501501501,97105060061500
       Other Liabilities 
0
0
0
0
50
88
1,971
150
150
150
2,560
3,202
2,802
1,435
0
0
0
5,818
6,697
11,792
9,049
8,192
6,563
5,390
3,712
1,412
1,252
649
228
0
0
2
0
0
0
0
0
0
0
0
000000002002286491,2521,4123,7125,3906,5638,1929,04911,7926,6975,8180001,4352,8023,2022,5601501501501,97188500000
       Deferred Long Term Liability 
0
0
0
0
0
0
1,846
0
0
150
2,410
3,202
2,802
1,435
0
0
0
5,818
6,697
11,792
9,049
0
6,563
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000006,56309,04911,7926,6975,8180001,4352,8023,2022,410150001,846000000
> Total Stockholder Equity
-222
-745
-688
17,231
16,244
14,960
16,142
19,269
18,651
17,118
20,570
16,748
14,968
14,272
14,682
22,092
18,975
15,571
15,292
15,629
14,467
17,760
88,516
84,700
81,259
78,993
72,665
66,359
58,417
52,191
45,684
40,268
35,138
26,073
21,587
17,705
7,479
5,979
42
-7,165
-7,165425,9797,47917,70521,58726,07335,13840,26845,68452,19158,41766,35972,66578,99381,25984,70088,51617,76014,46715,62915,29215,57118,97522,09214,68214,27214,96816,74820,57017,11818,65119,26916,14214,96016,24417,231-688-745-222
   Common Stock
7
7
7
11
12
12
18
21
21
21
26
27
27
29
34
45
46
46
53
60
62
69
28
29
29
29
29
29
29
29
30
30
30
33
2
3
3
3
14
30
3014333233303030292929292929292869626053464645342927272621212118121211777
   Retained Earnings -167,443-159,803-153,367-151,485-140,893-136,574-131,604-121,335-115,726-109,750-101,835-95,065-86,454-79,677-72,810-69,984-65,605-61,361-56,916-54,277-50,882-40,770-39,561-35,763-31,618-30,397-26,356-23,571-21,532-16,407-14,480-11,295-8,429-5,004-4,675-3,251-2,076-1,081-748-224
   Accumulated Other Comprehensive Income 
-5
0
-3
-3
-3
-6
0
-34
0
0
-32
6
21
35
24
22
19
31
-2
23
33
65
61
55
39
41
53
22
3
12
8
7
-3
-9
-18
-10
4
-41
-38
-38
-38-38-414-10-18-9-378123225341395561653323-23119222435216-3200-340-6-3-3-30-5
   Capital Surplus 
0
0
388
19,299
19,486
19,623
21,128
27,711
29,925
31,577
36,951
38,247
38,491
40,564
45,021
53,643
54,673
55,055
56,011
66,428
68,649
74,671
149,788
150,231
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000150,231149,78874,67168,64966,42856,01155,05554,67353,64345,02140,56438,49138,24736,95131,57729,92527,71121,12819,62319,48619,29938800
   Treasury Stock0000000000000000000000000000000000000000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-126
Gross Profit-126-126
 
Operating Income (+$)
Gross Profit-126
Operating Expense-26,641
Operating Income-26,641-26,767
 
Operating Expense (+$)
Research Development17,729
Selling General Administrative8,786
Selling And Marketing Expenses0
Operating Expense26,64126,515
 
Net Interest Income (+$)
Interest Income550
Interest Expense-0
Other Finance Cost-0
Net Interest Income550
 
Pretax Income (+$)
Operating Income-26,641
Net Interest Income550
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-21,763-31,519
EBIT - interestExpense = -21,763
-21,763
-21,763
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-21,763-21,763
Earnings Before Interest and Taxes (EBITDA)-21,637
 
After tax Income (+$)
Income Before Tax-21,763
Tax Provision-0
Net Income From Continuing Ops-21,763-21,763
Net Income-21,763
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses26,641
Total Other Income/Expenses Net4,878-550
 

Technical Analysis of Moleculin
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Moleculin. The general trend of Moleculin is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Moleculin's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Moleculin Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Moleculin Biotech Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 0.423 < 0.5327 < 0.62.

The bearish price targets are: 0.3474 > 0.25.

Know someone who trades $MBRX? Share this with them.πŸ‘‡

Moleculin Biotech Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Moleculin Biotech Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Moleculin Biotech Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Moleculin Biotech Inc. The current macd is -0.05460963.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Moleculin price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Moleculin. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Moleculin price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Moleculin Biotech Inc Daily Moving Average Convergence/Divergence (MACD) ChartMoleculin Biotech Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Moleculin Biotech Inc. The current adx is 29.27.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Moleculin shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Moleculin Biotech Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Moleculin Biotech Inc. The current sar is 0.348632.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Moleculin Biotech Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Moleculin Biotech Inc. The current rsi is 42.36. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Moleculin Biotech Inc Daily Relative Strength Index (RSI) ChartMoleculin Biotech Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Moleculin Biotech Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Moleculin price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Moleculin Biotech Inc Daily Stochastic Oscillator ChartMoleculin Biotech Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Moleculin Biotech Inc. The current cci is -23.13240236.

Moleculin Biotech Inc Daily Commodity Channel Index (CCI) ChartMoleculin Biotech Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Moleculin Biotech Inc. The current cmo is -7.31238808.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Moleculin Biotech Inc Daily Chande Momentum Oscillator (CMO) ChartMoleculin Biotech Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Moleculin Biotech Inc. The current willr is -14.55026455.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Moleculin Biotech Inc Daily Williams %R ChartMoleculin Biotech Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Moleculin Biotech Inc.

Moleculin Biotech Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Moleculin Biotech Inc. The current atr is 0.0466145.

Moleculin Biotech Inc Daily Average True Range (ATR) ChartMoleculin Biotech Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Moleculin Biotech Inc. The current obv is 445,551,932.

Moleculin Biotech Inc Daily On-Balance Volume (OBV) ChartMoleculin Biotech Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Moleculin Biotech Inc. The current mfi is 48.97.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Moleculin Biotech Inc Daily Money Flow Index (MFI) ChartMoleculin Biotech Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Moleculin Biotech Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-04-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-05RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-16RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-07-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-07-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-07-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-01CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-08-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-09-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-09-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Moleculin Biotech Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Moleculin Biotech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.363
Ma 20Greater thanMa 500.433
Ma 50Greater thanMa 1000.569
Ma 100Greater thanMa 2000.657
OpenGreater thanClose0.389
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Moleculin with someone you think should read this too:
  • Are you bullish or bearish on Moleculin? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Moleculin? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Moleculin Biotech Inc

I send you an email if I find something interesting about Moleculin Biotech Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Moleculin Biotech Inc.

Receive notifications about Moleculin Biotech Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.